Both stocks run through our valuation models. Here is how Biogen (BIIB) and Eli Lilly and (LLY) compare, as of Aug 14, 2026.
As of Aug 14, 2026, Fair Value Calculator sees Biogen as the less overvalued of the two: Biogen trades at $211 versus a fair value of $190 (-10%), while Eli Lilly and trades at $1,209 versus $389 (-68%).
Biogen
BIIB · USD · Health Care
-10%
upside to fair value
overvalued
Price$211
Fair Value$190
Quality65/100
Eli Lilly and
LLY · USD · Health Care
-68%
upside to fair value
overvalued
Price$1,209
Fair Value$389
Quality69/100
Head-to-head numbers
Green value = the better side for that row (for valuation multiples: lower = cheaper).
BiogenEli Lilly and
Valuation
22.4×P/E (TTM)42.2×
3.10×P/S (TTM)14.67×
1.69×P/B39.94×
9.6×EV/EBITDA30.2×
4.16×PEG1.54×
—Dividend yield0.5%
—Dividend per share$6.23
Profitability
14%Net margin35%
23%Operating margin49%
8%Return on equity107%
6%Return on assets21%
Growth
2%Revenue growth (YoY)56%
-1.2%Avg. growth/yr (3Y)31.7%
-6.1%Avg. growth/yr (5Y)21.6%
Balance & size
0.34×Debt / equity1.54×
$31BMarket cap$1.1T
weakGrowth qualitymixed
Eli Lilly and leads: 5 to 8 metric wins.
Dash = not meaningfully computable, for example with negative equity.
Quality in detail
The quality score, broken down into the same factor families as on the stock page, 0 to 100 per family.
Biogenof which business quality 63 · market factors 77Eli Lilly andof which business quality 65 · market factors 83
ProfitabilityMargins and returns on capital today
38
85
Quality GrowthAre margins and returns improving?
32
86
CashflowEarnings quality: real cash, not paper profit
InvestmentDisciplined investing over empire-building
72
15
Low VolatilityCalm price path (market factor)
78
77
MomentumPrice trend over the last 3–12 months (market factor)
67
79
52W MomentumDistance to the 52-week high (market factor)
95
97
Net IssuanceBuybacks instead of dilution
78
93
What the models say
The median fair value (base case) per model family, each in the currency of its trading venue. Green = above the current price, red = below.
Biogen
DCF Models$294
Earnings-Based$136
Dividend Discount$0.09
Multiples$171
Asset-Based$82.85
Growth DCF$294
Economic Profit$105
Growth Earnings$207
14 of 26 models see the stock below the current price.
Eli Lilly and
DCF Models$334
Earnings-Based$239
Dividend Discount$115
Multiples$358
Asset-Based$19.94
Growth DCF$187
Economic Profit$347
Growth Earnings$375
26 of 26 models see the stock below the current price.
Scenario ranges
From our cautious bear case to the optimistic bull case. The white tick is the current price: left of fair value means room to run.
Biogen
Bear $135Fair Value $190Bull $241
$211 = current price (white tick)
Eli Lilly and
Bear $216Fair Value $389Bull $582
$1,209 = current price (white tick)
Compare two other stocks
Tap a field and type again, ticker or company name.
Free, no sign-up
Ranked within their sector
Where each stock sits within its sector peer group. Band = middle 50% of peers, tick = median, dot = this stock.
Biogen · Health Care
Quality score65 · Top 25%
Fair value upside-10% · above median
Eli Lilly and · Health Care
Quality score69 · Top 25%
Fair value upside-68% · bottom 25%
Bottom line
As of Aug 14, 2026, Fair Value Calculator sees Biogen as the less overvalued of the two: Biogen trades at $211 versus a fair value of $190 (-10%), while Eli Lilly and trades at $1,209 versus $389 (-68%).
Eli Lilly and has the higher quality score (69/100).
Just your email for the monthly Top-25 report of the most undervalued quality stocks, with fair value, quality and price target. Plus 14 days of Pro to try, no card.
Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click. Not financial advice.
A model-based valuation snapshot from 21 models. Values change with price and fundamentals; the date shown above applies.
